|
|
Volumn 30, Issue 2, 2012, Pages 128-131
|
|
Fresh from the biotech pipeline 2011
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AFLIBERCEPT;
ASPARAGINASE;
AZFICEL T;
BELATACEPT;
BELIMUMAB;
BRENTUXIMAB VEDOTIN;
CRIZOTINIB;
DACARBAZINE;
ECULIZUMAB;
EYLEA;
IPILIMUMAB;
PEGINTERFERON ALPHA2B;
RUXOLITINIB;
SIPULEUCEL T;
TOCILIZUMAB;
UNCLASSIFIED DRUG;
VEMURAFENIB;
ACUTE LYMPHOBLASTIC LEUKEMIA;
CANCER SURVIVAL;
COMPARATIVE EFFECTIVENESS;
DRUG APPROVAL;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG TARGETING;
FOOD AND DRUG ADMINISTRATION;
GRAFT REJECTION;
HEMATOLOGIC MALIGNANCY;
HEMOLYTIC UREMIC SYNDROME;
HODGKIN DISEASE;
HUMAN;
JUVENILE RHEUMATOID ARTHRITIS;
LARGE CELL LYMPHOMA;
MELANOMA;
MYELOFIBROSIS;
MYELOPROLIFERATIVE DISORDER;
PRIORITY JOURNAL;
PROSTATE CANCER;
RETINA MACULA AGE RELATED DEGENERATION;
REVIEW;
SURVIVAL RATE;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TREND STUDY;
ARGENTINA;
BIOTECHNOLOGY;
BRAZIL;
FRANCE;
GERMANY;
HUMANS;
INDUSTRY;
MALAYSIA;
SCOTLAND;
|
|
EID: 84856720002
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt.2111 Document Type: Review |
|
Times cited : (9)
|
|
References (7)
|
